Informations sur le stock Basilea Pharmaceutica | Filter  Basic-Info

Basilea Pharmaceutica

The past 10 years the (international) industry gained at around 75 percent. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 75 percent.

The past year gave good returns for Basilea Pharmaceutica investors

Over the last 12 months, that were loss-making period for the investors in Basilea Pharmaceutica, the stock lost around 22 percent. Over the period from December 2011 till December 2016 the stock rose on average 139 percent. Basilea Pharmaceutica's revenues between 2011 and 2015 were very constant and moved between 57,88 million CHFF and 51,65 million CHFF. The net results between 2011 and 2015 were very constant and fluctuated between -57,65 million CHFF and -61,6 million CHFF.

Basilea Pharmaceutica paid out dividends in the past 5 years. Basilea Pharmaceutica's dividend return over the period 2011 - 2015 was around 5 percent per year.

At the end of 2015 Basilea Pharmaceutica employed at around 23 people.

Basilea Pharmaceutica financed with a quite low debt position

As per the end of 2015 the Swiss company's balance sheet equaled 398,74 million CHFF. The total debt of the pharmaceutical company was at the end of 2015 383,88 million CHFF, which equals around 96,27 percent of the total balance sheet. Last year the pharmaceutical company's price/earnings-ratio (PE) was around -15. So the investors valued the stock at -15 times 2015' earnings per share. We could say that based on her price/earnings-ratio and dividend yield the Swiss stock can be seen as a value stock.

At the end of 2015 the Swiss company's market capitalization equaled around 958,64 million CHFF. At the end of 2015 the Swiss company had around 10,11 million stocks listed.

All the annual reports of Basilea Pharmaceutica are available here. More information about Basilea Pharmaceutica can be found it's website. .